Perspective
When Cost-Effectiveness Thresholds Drift: Global HTA, MFN Pricing, and the Need for a Coherent Framework
May 28, 2026
Featured Experts: William Padula, PhD
Research
All Research Featured Research
News
New Financing Models May Expand Access to Life-Changing Cell and Gene Therapies
March 19, 2026
Featured Experts: Alison Sexton Ward, PhD, Elizabeth Fowler, PhD, JD, Jeremy L. Shane, Darius Lakdawalla, PhD
White Paper
High-Stakes Medicine: Rethinking Policies for the Cost and Value of Cell and Gene Therapies
March 19, 2026
Featured Experts: Alison Sexton Ward, PhD, Elizabeth Fowler, PhD, JD, Jeremy L. Shane, Darius Lakdawalla, PhD
News
Schaeffer Scholar Receives 2025 ISPOR Research Methodology Award
October 24, 2025
Featured Experts: Boshen Jiao, PhD, MPH
Comment Letter
Response to the Draft Report of the Health Economics Methods Advisory (HEMA): “Defining Appropriate Benefits for Economic Evaluation of Health Care Technologies”
October 21, 2025
Featured Experts: Alice Chen, PhD, Jason Doctor, PhD, Dana Goldman, PhD, Darius Lakdawalla, PhD, Barry Liden, JD, Karen Mulligan, PhD, Desi Peneva, MS, Charles E. Phelps, PhD
Journal Article
Measuring the Budget Impact of Nondiscriminatory Cost-Effectiveness
September 5, 2025
Featured Experts: Karen Mulligan, PhD, Drishti Baid, MPP, Maria-Alice Manetas, Darius Lakdawalla, PhD
Comment Letter
Comments to USTR on Foreign Nations Freeloading on American-Financed Innovation
June 27, 2025
Featured Experts: Dana Goldman, PhD, Darius Lakdawalla, PhD, Barry Liden, JD
Perspective
Ensuring Most-Favored Nation Drug Pricing Doesn’t Sicken Us
May 20, 2025
Featured Experts: Darius Lakdawalla, PhD, Dana Goldman, PhD
Perspective
Alternatives to the QALY for Comparative Effectiveness Research
April 21, 2023
Featured Experts: Darius Lakdawalla, PhD, Charles E. Phelps, PhD
Comment Letter
Comments to CMS on the Inflation Reduction Act’s Drug Price Negotiation Program
April 17, 2023
Featured Experts: Dana Goldman, PhD, Charles E. Phelps, PhD, Darius Lakdawalla, PhD, Joseph Grogan, JD, Karen Van Nuys, PhD, Barry Liden, JD, William Padula, PhD
White Paper
Mitigating the Inflation Reduction Act’s Adverse Impacts on the Prescription Drug Market
April 13, 2023
Featured Experts: Dana Goldman, PhD, Joseph Grogan, JD, Darius Lakdawalla, PhD, Barry Liden, JD, Erin Trish, PhD
Perspective
Addressing Value Defects from Wasteful Services through Health Technology Assessment
March 6, 2023
Featured Experts: William Padula, PhD
Perspective
Value Defects In The Health Services Sector
May 4, 2022
Featured Experts: William Padula, PhD
Perspective
California Should Lead on Health Technology Assessment
January 27, 2022
Featured Experts: Darius Lakdawalla, PhD, Dana Goldman, PhD
Perspective
How COVID Can Help Us Refocus on the How and Why of Value Assessment
October 21, 2021
Featured Experts: Darius Lakdawalla, PhD, Charles E. Phelps, PhD
Perspective
Federal Government Should Advise on Drug Negotiations, Not Run Them
September 23, 2021
Featured Experts: Karen Mulligan, PhD, Darius Lakdawalla, PhD
Perspective
Create a U.S. Institute of Health Technology Assessment to Preserve Innovation and Control Costs
March 5, 2021
Featured Experts: Darius Lakdawalla, PhD
